Home Tags Drug Development
Drug Development Related Content
In the view of Amanda Feilding, Founder of the Beckley Foundation, “Psychedelics are unique pharmacological compounds that hold the promise of a profound paradigm shift in psychiatry.” Here, we learn about the Psychedelic Renaissance and the importance of drug policy reform.
The Beckley Foundation initiates and supports research into psychedelic compounds to better understand their effects and medical applications.
Researchers at Cambridge have found that 'green' asthma inhalers would both reduce carbon emissions and reduce drug costs.
Here, we look at medical devices policy of Japan’s Ministry of Health, Labour and Welfare. The Ministry now has Katsunobu Katō in place, who very recently replaced Nemoto Takumi as the Minister of Health, Labour and Welfare in the country.
Prof Colin J Suckling OBE DSc FRSE from the Department of Pure & Applied Chemistry, at University of Strathclyde, explains the importance of getting your chemistry right.
Koichi Watashi, Senior Researcher from the National Institute of Infectious Diseases, Japan, explores the trick for cell invasion in reaching regulation of hepatitis B entry.
Chiara Frazzoli and Alberto Mantovani from Istituto Superiore di Sanità share their insights into endocrine disruptors and non-communicable diseases in Africa, in collaboration with NOODLES Alliance Network.
The EU-funded project FLEXPOL (GA number 721062) offers an affordable approach to prohibit the spread of bacteria and healthcare-associated infections using cost-effective and sustainable film products.
Versus Arthritis speaks to award-winning rheumatologist Dr Fiona Watt about clinical research into osteoarthritis.
Prof Dr Freimut Schliess, Director, Science & Innovation at Profil GmbH, sheds light on how Clinical Contract Research Organisations are building the digital bridge connecting clinical research and clinical care.
Here Dr. Harneet Arora, freelance neurologist, and FDA regulations expert, shares her advice on how to submit an application with FDA approval.
Diabetes UK and JDRF have announced their continued commitment to revolutionising Type 1 diabetes treatment, by awarding £490,000 to fund the next generation of immunotherapy research.
The University of Manchester found that a drug used for erectile dysfunction can slow or even reverse the progression of heart failure of sheep.
A five-year license has been issued to two companies allowing the cultivation and processing of medical cannabis products.
King's College London researchers found that cannabidiol (CBD) could hold promise as a treatment for psychosis, according to reasonable benefits seen in a clinical trial.
While Africa has made progress in tackling tuberculosis (TB), it still has one of the highest TB rates in the world and remains a priority.
Oxford Cannabinoid Technologies is a biopharmaceutical company combining cannabinoid medicine with world class scientific research and drug development.
On the 4th February 2019, a scientific breakthrough for the future of Alzheimer's brain reserach has been published - read on to explore the developments.
UCL’s Translational Research Office (TRO) builds on an increasingly vibrant translational culture across the university community.
English patients living in poorer areas are likely to be prescribed more opioids for pain by their GPs, according to a study led by University of Manchester and University of Nottingham researchers.
12Page 1 of 2